You are here: Industry Insights > Novartis

News List

Novartis to In-License ECF843 for Ophthalmic Indications americanpharmaceuticalreview
April 07, 2017
Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe).
Novartis’ lung cancer drug combination receives EU approval europeanpharmaceuticalreview
April 06, 2017
The European Commission has approved Novartis’ Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
Novartis drug combination Tafinlar + Mekinist receives EU approval for BRAF V600-positive advanced N cphi-online
April 05, 2017
New indication of Tafinlar and Mekinist in advanced NSCLC provides only therapy approved in the EU for BRAF V600-positive NSCLC.
Novartis investigational CAR-T therapy gets FDA priority review pharmafile
March 30, 2017
Novartis’ investigational chimeric antigen receptor T cell (CAR-T) therapy CTL019 (tisagenlecleucel-T) has been awarded has been awarded priority review by the FDA for the treatment of relapsed and refractory B-cell acute lymphoblastic leukaemia (ALL) in
Novartis laterals two PhII anti-aging drugs to a PureTech startup, grabbing an equity stake endpts
March 24, 2017
Pharma giant Novartis is spinning out a pair of Phase IIb-ready drugs now bound for advanced trials on repairing the deteriorating impact of aging on the human immune system.
Novartis' serelaxin fails to meet goals of late-stage acute heart failure study firstwordpharma
March 23, 2017
Novartis announced Wednesday that a Phase III study of the experimental drug serelaxin in patients with acute heart failure (AHF) failed to meet its primary endpoints...
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis worldpharmanews
March 23, 2017
Novartis has announced new data suggesting, for the first time, that Cosentyx® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1].
Novartis says Cosentyx can potentially modify the course of psoriasis in certain patients firstwordpharma
March 22, 2017
Novartis on Tuesday unveiled data from a Phase III study suggesting that Cosentyx (secukinumab) can alter the course of moderate-to-severe psoriasis resulting in long-term, treatment-free skin clearance in some patients.
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart fa worldpharmanews
March 21, 2017
Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes...
Novartis heart-failure med Entresto cuts A1c biospectrumasia
March 21, 2017
Entresto is indicated to reduce the risk of cardiovascular (CV) death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page